DAC group raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
While it is thus possible to use uranium-233 as the fissile material of a nuclear weapon, speculation aside, there is scant publicly available information on this isotope actually having been weaponized:
=== Non-intoxicating effects === Cannabidiol does not appear to have any intoxicating effects such as those caused by ∆9-THC in cannabis, but it is under preliminary research for its possible anxiolytic and antipsychotic effects. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical cannabis" (with varying degrees of psychotropic effects and deficits in executive function) from "medical CBD therapies", which would commonly present as having a reduced or non-psychoactive side-effect profile. Various strains of "medical cannabis" are found to have a significant variation in the ratios of CBD-to-THC and are known to contain other non-psychotropic cannabinoids. Any psychoactive cannabis, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. As defined by US federal law, non-psychoactive hemp (also commonly termed "industrial hemp"), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆9-tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis. In the United States, certain standards are required for legal growing, cultivating, and producing the hemp plant, but there are no federal standards for quality being enforced in the hemp industry. Certain state regulations are in place, but vary state to state. For instance, the Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0.3%.
They gained promotion to the Championship following a 3–1 win over Millwall in the play-off final later that season. In September 2016, Barnsley were caught up in an ongoing scandal in English football, with assistant manager Tommy Wright alleged to have accepted "bungs" in exchange for working as an ambassador for a third-party player ownership consortium. Wright was suspended and subsequently dismissed by the club.
While artesunate is used primarily as treatment for malaria, there is some evidence that it may also have some beneficial effects in Schistosoma haematobium infection, but has not been evaluated in large randomized trials. Artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinine.
The ability to acquire a large number of chemists and engineers quickly was a huge contribution to the success of DuPont's nylon project. The first nylon plant was located at Seaford, Delaware, beginning commercial production on December 15, 1939. On October 26, 1995, the Seaford plant was designated a National Historic Chemical Landmark by the American Chemical Society.
Sources: en.wikipedia.org
=== Healthcare === Talarico supports healthcare reform and universal healthcare as a human right. He supports making buy-in Medicare or a public health insurance option available to every American, calling his healthcare plan "Medicare for Y'all". In August 2026, Talarico unveiled a healthcare plan focused on breaking up vertically integrated healthcare companies, including pharmacy benefit managers, insurance companies, and hospital networks. The proposal included measures to increase transparency in pharmacy benefit manager pricing, encourage the development and approval of generic drugs, and cap out-of-pocket healthcare costs.
== History == Translationally controlled tumor protein was first discovered in 1989 as a cDNA sequence obtained from a human mammary carcinoma cDNA library with proves derived from the translationally controlled, growth-related mouse tumor protein TCTP. TCTP was originally described as a growth related protein of tumor cells. Its mRNA accumulates in translationally repressed postpolysomal mRNP-complexes. Research in 1997 shown that TCTP is not a tumor- or tissue-specific protein, but is expressed ubiquitously from plants to mammals. Later studies show TCTP involvement in a protozoan Trypanosoma brucei.
Upon learning that the Top Hat name was already trademarked, Smith and Pappe changed its name to the Sonic brand in 1959. The new name worked with their existing slogan, "Service with the Speed of Sound". After the name change, the first Sonic sign was installed at the Stillwater Top-Hat Drive-In. This was the first of three Sonics in Stillwater. The original Sonic with the first sign was demolished and renovated in May 2015. Although Smith and Pappe were being asked to help open new franchise locations, no real royalty plan was in place. The pair decided to have their paper company charge an extra penny for each Sonic-label hamburger bag it sold. The proceeds would then be split between Smith and Pappe. The first franchise contracts under this plan were drawn up, but still no joint marketing plan, standardized menu, or detailed operating requirements were in place.
=== Vomiting === The vomiting center in the medulla, called the area postrema, contains low concentrations of Substance P and its receptor, in addition to other neurotransmitters such as choline, histamine, dopamine, serotonin, and endogenous opioids. Their activation stimulates the vomiting reflex. Different emetic pathways exist, and Substance P/NK1R appears to be within the final common pathway to regulate vomiting.
Later on, his statements about doping in the Bundesliga were supported by Per Roentved, Hans Werner Moors, Dieter Schatzscheider, Hans-Josef Kapellmann, Peter Neururer, Benno Möhlmann, Uwe Nester, Peter Geyer (who talked about procedure, quantity and side effects), Jürgen Röber, Jürgen Stumm and Peter Harms (both medics). At Olympique Marseille, doping took place according to Marcel Desailly, Jean-Jacques Eydelie, Chris Waddle, and Tony Cascarino. They told about stimulants taken prior to their big games, which made them more energetic and keen. According to Eydelie, "all [of them] took a series of injections" in the 1993 Champions League final, except Rudi Völler. All this was no surprise for Arsene Wenger, who said everyone in France assumed something like that going on. Additionally, Desailly and Cascarino claimed that Bernard Tapie, the president himself, distributed pills and injections. Author Mondenard also mentioned "injections for everyone". Tapie only admitted that some players took Captagon. Although Juventus won the 1996 Champions League final, the victory was overshowed by of accusations of doping. The Juventus team has been accused of using erythropoietin (EPO) and the matter went to trial in 2004.
Sources: en.wikipedia.org
== Further reading == Blanco, Carlos; Alegría, Analucía A.; Liu, Shang-Min; Secades-Villa, Roberto; Sugaya, Luisa; Davies, Carrie; Nunes, Edward V. (2012). "Differences Among Major Depressive Disorder with and Without Co-occurring Substance Use Disorders and Substance-Induced Depressive Disorder". The Journal of Clinical Psychiatry. 73 (6): 865–873. doi:10.4088/JCP.10m06673. PMID 22480900. Sciacca, Kathleen_2009. "Best Practices for Dual Diagnosis Treatment and Program Development: Co-occurring Mental Illness and Substance Disorders in Various Combinations". In Angela Brown-Miller (ed.). The Praeger International Collection on Addictions. Vol. 3. Praeger. pp. 161–188.{{cite book}}: CS1 maint: numeric names: authors list (link) Sciacca, K. (2011). "Integrated Group Treatment for People Experiencing Mental Health - Substance Use Problems". In David B. Cooper (ed.). Intervention in Mental Health - Substance Use. Radcliffe Pub. pp. 114–127. Sciacca, K.; Hatfield, A. B. (1995). "The Family and the Dually Diagnosed Patient". In Lehman, A. F.; Dixon, L. B. (eds.). Double Jeopardy. Harwood Academic Publishers. pp. 193–209. Giglioti, M. A. (October 1986). "Program Initiatives for Dually-Diagnosed at Harlem Valley Psychiatric Center. Dual Diagnosis -Co-occurring Disorders". New York State Commission on Quality of Care Publication (28). Samet S, Nunes E, Hassin D, et al. (2006). "Diagnosis of comorbid psychiatric disorders in substance users assesses with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV". American Journal of Psychiatry.
The HHS Proficiency Examination (formerly HEW Proficiency Examination) refers to an American medical technologist certification offered by the Department of Health Education and Welfare (HEW) and subsequently United States Department of Health and Human Services (HHS). The examination was established under Social Security Amendments of 1972 and was offered seven times from 1975 until 1987. The HEW/HHS exam qualified individuals to serve as high complexity general supervisors under Clinical Laboratory Improvement Amendments(CLIA) 1992 without a degree. The exam was administered a total of 7 times: 4 times between 1975 and 1977, once in 1979 and once in 1983, and one last time on August 28, 1987. Approximately 65,000 people took the exam, and approximately 31,000 passed. Several other allied health profession proficiency examinations were included in the original act, but only the laboratory examination was renewed. The qualifications for the HEW exam were a GED and 4 year of on-the-job laboratory experience. Over a dozen medical technologist professional associations opposed the certification including the American Society of Clinical Pathologists (ASCP) and American Medical Technologists (AMT). Opposition was in part due to the lack of educational requirements, another competing certification in a crowded field, and a lack of follow-up efficacy.
The following outline is provided as an overview of and topical guide to biochemistry: Biochemistry, or biological chemistry (distinct from chemical biology), is the study of chemical processes within and relating to living organisms. A sub-discipline of both chemistry and biology, biochemistry may be divided into three fields: structural biology, enzymology, and metabolism. Over the last decades of the 20th century, biochemistry has become successful at explaining living processes through these three disciplines. Almost all areas of the life sciences are being uncovered and developed through biochemical methodology and research.
== Characteristics == Elastin is a very long-lived protein, with a half-life of over 78 years in humans. However, its long lifespan does not imply that its functional properties remain unchanged throughout life. In human skin, ageing is associated with changes in the amount, organisation and integrity of dermal elastic fibres. An in vivo multiphoton tomography study reported age-related reductions in the measured elastin and collagen content of the human dermis. More recent three-dimensional imaging of human dermal elastin has shown that the number of elastic fibres decreases with age and that the remaining network becomes more fragmented and less interconnected. Finite-element modelling based on these structural observations associated age-related changes in elastin-fibre architecture with reduced skin firmness.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.